Replimune Group, Inc. stock analysis
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicat
- Ticker
- REPL
- Exchange
- Nasdaq
- Sector
- Health Care
- Industry
- Pharmaceuticals
What should I review before buying Replimune Group, Inc. stock?
Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.
Inside the full analysis
- Valuation
- Growth
- Financial health
- Ownership
- Research
Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.
Sign in to open the analysis